Mass Balance Study of the Engineered Cationic Antimicrobial Peptide, WLBU2, Following a Single Intravenous Dose of 14C-WLBU2 in Mice | Zendy

Jan H. Beumer | Zendy; Jianxia Guo | Zendy; Evan C. Ray | Zendy; Jonas Scemama | Zendy; Robert A. Parise | Zendy; Berthony Deslouches | Zendy; Jonathan D. Steckbeck | Zendy; Ronald C. Montelaro | Zendy; Julie L. Eiseman | Zendy

Open Access

Mass Balance Study of the Engineered Cationic Antimicrobial Peptide, WLBU2, Following a Single Intravenous Dose of 14C-WLBU2 in Mice

Author(s) -

Jan H. Beumer,

Jianxia Guo,

Evan C. Ray,

Jonas Scemama,

Robert A. Parise,

Berthony Deslouches,

Jonathan D. Steckbeck,

Ronald C. Montelaro,

Julie L. Eiseman

Publication year - 2020

Publication title -

current reviews in clinical and experimental pharmacology

Language(s) - English

Resource type - Journals

eISSN - 2772-4336

pISSN - 2772-4328

DOI - 10.2174/1574884715666200810094201

Subject(s) - antimicrobial , peptide , cationic polymerization , balance (ability) , antimicrobial peptides , chemistry , pharmacology , medicine , microbiology and biotechnology , biochemistry , biology , physical medicine and rehabilitation , organic chemistry

To address multidrug resistance, we developed engineered Cationic Antimicrobial Peptides (eCAPs). Lead eCAP WLBU2 displays potent activity against drug-resistant bacteria and effectively treats lethal bacterial infections in mice, reducing bacterial loads to undetectable levels in diverse organs.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research

Address

John Eccles House
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom

About

About Careers Publisher Partners Contact Us Our institutional solutions Get Organisational Trial or Quote

Learn

FAQs Blog Terms of Use Privacy Policy

Download the Zendy App

Discover

Explore

Home ZAIA Blog